Aleix Prat: The high costs of anticancer therapies in the USA
Aleix Prat shared the following on X:
“The high costs of anticancer therapies in the USA: challenges, opportunities, and progress in Nature Reviews Clinical Oncology.
Addressing the financial burden requires collaboration across healthcare. Equally important is investing in diagnostic tools to better tailor treatments and improve outcomes.
Read more.”
The high costs of anticancer therapies in the USA: challenges, opportunities and progress
Authors: Shelley A. Jazowski, Rahul K. Nayak & Stacie B. Dusetzina
Source: Aleix Prat/X
Aleix Prat is the Director of the Cancer Institute at Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona. He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023